A PREFERRED 1L REGIMEN OPTION (CATEGORY 1 RECOMMENDATION)10

Albumin-bound paclitaxel (ABRAXANE) + gemcitabine is a preferred 1L regimen per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for metastatic pancreatic cancer in patients with good performance status PS 0 or 1 and in some patients with PS 2 (KPS ≥70; NCCN supports initiating albumin-bound paclitaxel (ABRAXANE 125 mg/m2 + gemcitabine given QW3/4 and treating until disease progression or unacceptable toxicity | Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicity Albumin-bound paclitaxel (ABRAXANE) + gemcitabine is a preferred 1L regimen per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for metastatic pancreatic cancer in patients with good performance status PS 0 or 1 and in some patients with PS 2 (KPS ≥70; NCCN supports initiating albumin-bound paclitaxel (ABRAXANE 125 mg/m2 + gemcitabine given QW3/4 and treating until disease progression or unacceptable toxicity | Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicity
Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicity

  • aCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.10
  • bGood performance status for this regimen (AG) is defined as KPS ≥70, so some patients with an ECOG score of 2 may be eligible to receive this regimen (AG).10
  • cAccording to the NCCN Chemotherapy Order Templates: Peer-reviewed statements of consensus of its authors derived from the NCCN Guidelines®.
  • The albumin-bound paclitaxel (ABRAXANE) Phase III MPACT study enrolled patients with KPS ≥70.10
    Good performance status is defined as ECOG 0-1, with good biliary drainage and adequate nutritional intake, and ECOG 0-2 if considering gemcitabine + albumin-bound paclitaxel.10
    Please refer to the NCCN Guidelines for pancreatic cancer for a complete list of recommended treatment options.
    AG=ABRAXANE + gemcitabine.

YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL